Abstract |
ICI 164384, a new steroidal antioestrogen, entirely devoid of oestrogenic activity, modulates doxorubicin resistance in vitro. At non-cytotoxic concentrations, ICI 164384 potentiated the cytotoxicity of doxorubicin in a dose-dependent manner in both the classical multi- drug resistant (MDR) human leukaemia cell lines CEM/VLB 100 and CEM/VLB 1000 and the human small cell lung cancer cell line H69 LX4. ICI 164384 had no effect on the two respective parental cell lines, CEM/CCRF and H69 P. None of these cell lines expressed the oestrogen receptor. In comparative studies at concentrations ranging from 1.25 to 10 mumols/l, ICI 164384 was significantly more effective (1.2-6-fold) than tamoxifen in reducing the IC50 of doxorubicin in the CEM/VLB 100 line. In resistant cells, ICI 164384 increased 3H-daunomycin accumulation in a dose-dependent manner and was significantly more effective than tamoxifen at concentrations ranging from 2.5 to 10 mumol/l. ICI 164384 reduced the efflux of daunomycin from resistant cells more effectively than tamoxifen. These studies suggest that ICI 164384 is an effective modulator of MDR.
|
Authors | X F Hu, G Nadalin, M De Luise, T J Martin, A Wakeling, R Huggins, J R Zalcberg |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 27
Issue 6
Pg. 773-7
( 1991)
ISSN: 0959-8049 [Print] England |
PMID | 1648945
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogen Antagonists
- Polyunsaturated Alkamides
- Estradiol
- Doxorubicin
- ICI 164384
- Daunorubicin
|
Topics |
- Carcinoma, Small Cell
(pathology)
- Cell Division
(drug effects)
- Cell Line
- Daunorubicin
(metabolism)
- Doxorubicin
(pharmacology)
- Drug Resistance
- Estradiol
(analogs & derivatives, pharmacology)
- Estrogen Antagonists
(pharmacology)
- Humans
- Leukemia, T-Cell
(metabolism, pathology)
- Lung Neoplasms
(pathology)
- Polyunsaturated Alkamides
- Tumor Cells, Cultured
(drug effects)
|